Seeking Alpha
15 Jun 2026, 17:59 UTC · 22w ago
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
Impact · against what's priced in
BioCryst (BCRX) receives a positive catalyst through the introduction of specific long-term financial targets for 2033 and the competitive positioning of navenibart. While Orladeyo's current growth is steady, the shift toward a multi-billion dollar franchise framework provides a concrete valuation floor.
- BCRX+0.50
No priced-in read yet
- In context
The company's target of $1.8 billion in revenues and $1 billion in cash by 2033, combined with the development of navenibart as a best-in-class treatment, provides a new long-term growth trajectory beyond current Orladeyo performance.
Read from the article alone

Top 1 mover · tap to explore




